114 results about "Diarrheal disease" patented technology

The present invention discloses a kind of externally applied plaster for treating infant heat diarrhea and its preparation process. The externally applied plaster is developed based on the physiological features of infant and pathological features and pathogenesis of infant heat diarrhea, and is prepared with 12 kinds of Chinese medicinal materials, including eucalyptus leaf, membrnaceous marshmarigold, European verbena, etc. and through decoction, concentrating, crushing, and other steps. The externally applied plaster has the functions of clearing away heat, promoting diuresis, regulating qi and middle Jiao, invigorating spleen and arresting diarrhea. It is used for treating infant heat diarrhea.

The invention relates to the technical field of veterinary medicines, and in particular relates to a traditional Chinese medicinal composition for pigs. The traditional Chinese medicinal composition consists of 6-14 parts of smoked plum, 6-14 parts of myrobalan, 4-8 parts of rhizoma picrorhizae, 2-6 parts of sanguisorba carbon, 2-6 parts of astragalus membranaceus, 8-12 parts of halloysitum rubrum, 6-10 parts of anemone chinensis, 2-6 parts of rhizoma atractylodis and 2-6 parts of liquorice. The traditional Chinese medicinal composition can be powder, granules or oral administration liquid. The traditional Chinese medicinal composition for the pigs, which is disclosed by the invention, is a pure traditional Chinese medicinal composition, does not contain any chemical medicaments, has no residue and no toxic or side effect, is high in safety and difficultly generates drug resistance; an application test in a pig farm shows that the traditional Chinese medicinal composition has good treating effects of bacterial diarrhea, viral diarrhea, nutritional diarrhea and diarrhea caused by other various reasons of piglets; the pharmaceutical effect is quick to take, a quick respond is realized; the using amount of medicines is small; the cost is reduced; the survival rate of piglets is obviously improved; the treatment rate can be over 95 percent; the price is low; the medication safety is realized; the drug resistance can be avoided; the traditional Chinese medicinal composition can be popularized and applied.

The invention discloses a breeding method of a new disease-resistance large white pig strain. The method includes the following steps that 1, a feed adding method is adopted to conduct an Escherichia coli infection experiment on weaned piglets of a core group in large white pigs, and an Escherichia coli resistant breeding basic group in the large white pigs is established; 2, concentration determination is conducted on cytokines of interleukin 1beta, interleukin 4, interleukin 6, interleukin 8, interleukin 10, transforming growth factor beta, tumor necrosis factor alpha and interferon gamma of an Escherichia coli resistant population in the basic group; reproductive performances are detected and selected, growth speeds, lean meat ratios and carcass quality characters, and a first generation is established; 3, a group subculture selective breeding method and a molecular-marker-assisted selection method are adopted. In this way, by the adoption of the breeding method of the new disease-resistance large white pig strain, after four to five generations, a vested breeding target is achieved gradually, a new-strain core group is established, and the morbidity of piglet diarrheal diseases is expected to be reduced.

With the goal of creating a combination vaccine against Shigella and other diarrheal pathogens we have constructed a prototype vaccine strain of Shigella flexneri 2a (SC608) that can serve as a vector for the expression and delivery of heterologous antigens to the mucosal immune system. SC608 is an asd derivative of SC602, a well-characterized vaccine strain, which has recently undergone several phase 1 and 2 trials for safety and immunogenicity. Using non-antibiotic asd-based plasmids, we have created novel constructs for the expression of antigens from enterotoxigenic E. coli (ETEC), including CFA / I (CfaB and CfaE) and the B-subunit from heat-labile enterotoxin (LTB) in Shigella vaccine strain SC608. Heterologous protein expression levels and cellular localization are critical to immune recognition and have been verified by immunoblot analysis. Following intranasal immunization (SC608(CFAI) and SC608(CFAI / LTB) of guinea pigs, serum IgG and IgA immune responses to both the Shigella LPS and ETEC antigens can be detected by ELISA. In addition, ELISPOT analysis for ASCs from cervical lymph nodes and spleen showed similar responses. All vaccine strains conferred high levels of protection against challenge with wild-type S. flexneri 2a using the Sereny test. Furthermore, serum from guinea pigs immunized with SC608 expressing CfaB and LTB contained antibodies capable of neutralizing the cytological affects of heat-labile toxin (HLT) on Chinese Hamster Ovary (CHO) cells. These initial experiments demonstrate the validity of a multivalent invasive Shigella strain that can serve as a vector for the delivery of pathogen-derived antigens.

The invention discloses a strain of Lactobacillus johnsonii and its application in diarrhea of piglets, lambs and calves. The strain is isolated from healthy pig feces and has good in-vitro probioticpotential and safety. The Lactobacillus johnsonii of the invention and other strains are jointly applied to young animals with diarrhea, and the strain has obvious prevention and treatment effects ondiarrhea cases of different degrees.

The invention discloses a pharmaceutical composition for preventing and controlling livestock diarrhea. The pharmaceutical composition is an agent prepared from the following raw medicinal materials in parts by weight: 1-4 parts of Chinese herbaceous peony, 1-5 parts of scutellaria baicalensis, 1-5 parts of coptis chinensis, 1-5 parts of angelica sinensis, 1-5 parts of rheum officinale, 1-5 parts of elecampane, 1-5 parts of betel nut, 1-5 parts of lonicerae flos, 1-5 parts of purslane, 1-5 parts of rhododendron micranthum leaf, 1-5 parts of polygonum viviparum, 1-4 parts of bergenia purpurascens and 1-4 parts of liquorice. Clinical veterinary use results prove that the medicine disclosed by the invention has an obvious effect used for treating diarrheal diseases of livestock such as yak, Tibetan sheep and the like. Moreover, compared with the current Western medicine used for treating livestock diarrhea, the medicine disclosed by the invention has the advantages that milking and milk vending of animal owners are not influenced during the milking period of cattle and sheep, the advantages are obvious, and a novel medication choice is provided for clinical treatment of livestock diarrhea diseases.